<DOC>
	<DOCNO>NCT00158951</DOCNO>
	<brief_summary>The purpose clinical investigation demonstrate safety effectiveness CONTAK® RENEWAL™ 2/4/4HE cardiac resynchronization therapy defibrillator ( CRT-D ) family EASYTRAK® 2 lead deliver LV-CRT BiV-CRT LV Offset patient heart failure indication ICD .</brief_summary>
	<brief_title>Device Evaluation Contak Renewal 2and Easytrak 2 - DECREASE-HF</brief_title>
	<detailed_description>This clinical investigation prospective , multi-center , randomize , double-blind study design enrol 360 patient 57 center demonstrate safety effectiveness therapy , CONTAK RENEWAL 2/4/4HE device EASYTRAK 2 lead .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Meet general indication CRTD device Moderate severe heart failure , define NYHA Class IIIIV despite optimal pharmacological heart failure therapy . A 12lead electrocardiogram ( ECG ) obtain 90 day prior enrollment document sinus rate &gt; 50 bpm , QRS duration ³ 150 m , PR interval £ 320 m measure two lead , Pwave duration &lt; 150 m measure lead V1 Creatinine £ 2.5 mg/dL obtain 14 day prior enrollment Left ventricular ejection fraction £ 35 % [ measure echo , multiple gated acquisition ( MUGA ) scan , cardiac catheterization , etc . ] 14 day prior enrollment Willing capable undergoing device implant participate test associate clinical investigation Have life expectancy 180 day , per physician discretion Age 18 , legal age give inform consent specific state national law Right bundle branch block morphology ( per World Health Organization Guidelines ) 12lead ECG obtain 90 day prior enrollment . Have previous cardiac resynchronization therapy , previous coronary venous lead , meet general indication antibradycardia pace Have neuromuscular , orthopedic , noncardiac condition prevents normal , unsupported walking Have atrial tachyarrhythmia permanent ( i.e. , terminate spontaneously terminate medical intervention ) persistent ( i.e. , terminate medical intervention , terminate spontaneously ) within 180 day prior enrollment Have hypersensitivity 0.7 mg dose dexamethasone acetate Have surgically uncorrected primary valvular heart disease Currently require dialysis Have chronic obstructive pulmonary disease ( COPD ) , define FEV1/FVC &lt; 60 % Have myocardial infarct , unstable angina , percutaneous coronary intervention , coronary artery bypass graft 30 day prior enrollment Have hypertrophic obstructive cardiomyopathy infiltrative cardiomyopathy ( e.g. , amyloidosis , sarcoidosis ) Have mechanical tricuspid prosthesis Enrolled concurrent study , without Guidant write approval , may confound result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Left Ventricular Lead</keyword>
	<keyword>Cardiac Resynchronization Therapy</keyword>
	<keyword>Congestive Heart Failure</keyword>
</DOC>